Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-12-01 00:00:00 ET · period of report 2022-11-30 · accession 0000899243-22-037329 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-01 | 2022-11-30 | LGND | HIGGINS JOHN L | CEO, Dir | F - Tax | $72.90 | -9,803 | 416.9K | -2% | -$714.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-30 | F | D | 9,803 | $72.90 | 416,928 | D | — | — |